Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world single-arm study of tiepefigrastim injection to prevent chemotherapy-induced neutropenia in breast cancer
ChiCTR2100048479Phase 4Recruiting
- Sponsor
- Quanzhou First Hospital
- Start
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tiepefigrastim in chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN), sponsored by Quanzhou First Hospital. Primary endpoint: Incidence of grade 3 or higher neutropenia after tiepefigrastim administration. Started Jul 2021; status: recruiting.
02
Drugs
tiepefigrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)febrile neutropenia (FN)
Beyond the preview
Go deeper on ChiCTR2100048479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048479.